Company Overview and News
Procter & Gamble Co (NYSE:PG) stock took a hit following its earnings announcement. Although the company beat on both revenue and net income, earnings guidance disappointed Wall Street. Most of its peers in the consumer defensive sector also saw stock price drops on slower-than-expected growth.
Unilever PLC and Nestlé SA struggled to raise prices in the first quarter, illustrating how the world’s largest consumer goods companies are facing increasingly fierce competition.
Most European stock benchmarks moved modestly higher Thursday, led by gains for commodity and industrial shares, as investors waded through a pile of corporate earnings reports.
International Business Machines Corp. rode the success of old technology to big gains at the end of last year, but investors will be looking for success from newer businesses in order to believe in Big Blue’s future.
April 16 (Reuters) - Benjamin Frost, global co-head of consumer retail investment banking at Morgan Stanley, has departed the bank and is in talks to join Goldman Sachs Group Inc, people familiar with the matter on Monday.
When it comes to acquisitions, salesforce.com, inc. (NASDAQ:CRM) is far from timid. The company’s co-founder and CEO, Marc Benioff, has pulled the trigger on many deals during the past few years. And the results have been mostly positive for the CRM stock price.
U.S. cosmetics maker Avon Products Inc has reached an agreement with Barington Capital to nominate the investor's chief executive officer, James Mitarotonda, to its board in exchange for avoiding a proxy contest, a filing on Monday showed.
(Reuters) - U.S. cosmetics maker Avon Products Inc (AVP.N) has reached an agreement with Barington Capital to nominate the investor’s chief executive officer, James Mitarotonda, to its board in exchange for avoiding a proxy contest, a filing on Monday showed.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET